Isoquinoline compounds and their use in treating AhR imbalance
The present invention is directed to novel compounds of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof. Pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, are also described. The invention is also directed to use of the compounds of Formula (I) for treating a condition in a mammal associated with AhR imbalance, such as an inflammatory disease or disorder.
1. A method of treating an inflammatory disorder selected from the group consisting of psoriasis, atopic dermatitis, vitiligo, acne, uveitis radiation dermatitis, COPD, asthma, multiple sclerosis, and inflammatory bowel disease, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound which is 2-isopropyl-5-(isoquinolin-3-yl)benzene-1,3-diol of the formula:
or a pharmaceutically acceptable salt, solvate or hydrate thereof to thereby treat the inflammatory disorder.
2. The method of claim 1 , wherein the compound is 2-isopropyl-5-(isoquinolin-3-yl)benzene-1,3-diol of the formula:
3. The method of claim 1 wherein the inflammatory disorder is selected from the group consisting of psoriasis, atopic dermatitis, and acne.
4. The method of claim 1 wherein the compound, or a pharmaceutically acceptable salt, solvate or hydrate thereof, is administered topically.
5. The method of claim 1 , wherein the compound is at least 90% pure by weight.
6. The method of claim 1 , wherein the compound is at least 95% pure by weight.
7. The method of claim 1 , wherein the compound is at least 98% pure by weight.
8. The method of claim 1 , wherein the compound is at least 99% pure by weight.
9. A method of treating an inflammatory disorder selected from the group consisting of psoriasis, acne, and atopic dermatitis, in a subject in need thereof, comprising administering to said subject a pharmaceutical composition comprising therapeutically effective amount of a compound which is 2-isopropyl-5-(isoquinolin-3-yl)benzene-1,3-diol of the formula:
or a pharmaceutically acceptable salt, solvate or hydrate thereof and a pharmaceutically acceptable carrier or diluent to thereby treat the inflammatory disorder.
10. The method of claim 9 , wherein the compound is 2-isopropyl-5-(isoquinolin-3-yl)benzene-1,3-diol of the formula:
11. The method of claim 9 , wherein the pharmaceutically acceptable carrier or diluent is suitable for topical administration.
12. The method of claim 9 , wherein the pharmaceutically acceptable carrier or diluent is suitable for a gel topical administration.
13. The method of claim 9 , wherein the pharmaceutically acceptable carrier or diluent is suitable for a cream topical administration.
14. The method of claim 9 , wherein the pharmaceutical composition is administered topically.
15. The method of claim 1 wherein the inflammatory disorder is selected from the group consisting of COPD and inflammatory bowel disease.
16. A method of treating an inflammatory disorder selected from the group consisting of COPD and inflammatory bowel disease, in a subject in need thereof, comprising administering to said subject a pharmaceutical composition comprising a therapeutically effective amount of a compound which is 2-isopropyl-5-(isoquinolin-3-yl)benzene-1,3-diol of the formula:
or a pharmaceutically acceptable salt, solvate or hydrate thereof and a pharmaceutically acceptable carrier or diluent to thereby treat the inflammatory disorder.
17. The method of claim 16 , wherein the compound is 2-isopropyl-5-(isoquinolin-3-yl)benzene-1,3-diol of the formula:
18. The method of claim 16 , wherein the pharmaceutically acceptable carrier or diluent is suitable for oral, parenteral or intranasal administration.
19. The method of claim 16 , wherein the pharmaceutically acceptable carrier or diluent is suitable for oral administration.
20. The method of claim 16 , wherein the pharmaceutically acceptable carrier or diluent is suitable for parenteral administration.
21. The method of claim 16 , wherein the pharmaceutical composition is administered orally.
22. The method of claim 16 , wherein the pharmaceutical composition is administered parenterally.
23. The method of claim 16 , wherein the pharmaceutical composition is administered by intranasal or oral inhalation.